This study was conducted to see the incidence of the lesions of Salivary Gland. All the cases of salivary tissues submitted to the Pathology Department of King Edward Medical University were taken at the end of year (Jan 2005-Dec2005) and reanalyzed. There were 42 cases of salivary glands, out of which 19(45%) were males and 23(55%) were females. Age range was 12-72 years. Major number of cases (17) were from parotid, whereas 15 were from submandibular, 04 and 06 were from sublingual and minor salivary glands like palate respectively. There were 25(59.52%) pleomorphic adenoma, 01(2.3%), 01(2.3%), 04(9.5%), 07(16.6%) were monomorphic adenoma, lymphoepithelioma, mucoepidermoid carcinoma, adenoid cystic carcinoma respectively. Only 04(9.5%) cases showed chronic sialadenitis.
Her-2 (ErbB-2) is an oncogene frequently overexpressed in breast and gastric adenocarcinomas, and anti-Her-2 targeted therapy can be given to such patients. Her-2 overexpression and role of anti-Her-2 targeted therapy in cases of gallbladder adenocarcinomas (GBC) are still debatable. Scoring protocols for Her-2 expression in breast and gastric carcinomas are standardized, however, not for carcinomas arising in other body organs like the gallbladder. This study is conducted to evaluate the expression of Her-2 in patients with GBC, which may benefit from targeted therapy. It is a cross-sectional study conducted on patients with GBC (n=63; 53 women and ten men). An automated immunohistochemical technique was used with an anti-ErbB2 antibody. Scoring was conducted according to the CAP (College of American Pathologists) criteria for breast cancer. Positive (3+) Her-2 staining was observed in 8/63 (12.7%). Nine cases (14.3%) showed equivocal staining (2+) pattern. All of the tumors showing Her-2 overexpression were moderately differentiated. This study indicates that a significant number of GBC cases show Her-2 overexpression. This subgroup may benefit from inhibitors of the Her-2 pathway. Standardization of scoring protocol for Her-2 expression in GBC is needed to better evaluate the predictive potential of Her-2 for the treatment of these tumors.
Background: The ovarian carcinomas are the most cause of death in women due to cancer. The most common and lethal gynecological malignancy is malignant epithelial tumor.p53 may be used as a marker to predict aggressive behavior and poor response to standard chemotherapy.
Objective: To observe the frequency of positive immunohistochemical expression of p53 in surface epithelial carcinoma.
Materials and methods: A cross-sectional study for immunohistochemical expression of p53 on 100 diagnosed cases of surface epithelial carcinoma was conducted in the department of Histopathology, Chughtai Institute of of Pathology, Lahore during a period of 6 months. Nuclear staining for p53 was considered as positive. Cases with more than 10% positivity in tumor cells were considered as positive.
Results: The mean age of patients and size of tumor were 48.70 ± 10.5 1 years and 9.83 ± 5.33 cm respectively. 25% (n=25) patients had low histologic grades while 75%(n=75) patients had high histological grades.47% (n=47)patients were p53 positive and 53% (n=53) patients were negative for immunohistochemical expression of p53.
Conclusion: The present study states p53 positivity in 47% cases of epithelial ovarian cancer and the data fits to the proposed dualistic pathway of ovarian carcinogenesis as expression of p53 positive cases in high grade cancers is statistically significant ( <0.05).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.